Advertisement

Topics

Conatus Pharma Stock Dives on Mixed Clinical Trial Results

20:00 EDT 4 Apr 2018 | BioSpace

Shares of Conatus Pharmaceuticals dropped 34.3 percent postmarket yesterday after the San Diego-based company announced mixed top-line results for its proof-of-concept trial in liver transplant patients with fibrosis or cirrhosis.

Original Article: Conatus Pharma Stock Dives on Mixed Clinical Trial Results

NEXT ARTICLE

More From BioPortfolio on "Conatus Pharma Stock Dives on Mixed Clinical Trial Results"

Advertisement
Quick Search
Advertisement
Advertisement